Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

RELMADA THERAPEUTICS, INC. Director's Dealing 2019

Oct 21, 2019

34465_dirs_2019-10-21_2dff9837-58ca-4223-a716-385afc4d52eb.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: RELMADA THERAPEUTICS, INC. (RLMD)
CIK: 0001553643
Period of Report: 2019-10-21

Reporting Person: Shenouda Maged (Director)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2019-10-21 Common Stock P 978 $23.00 Acquired 2228 Direct